Daniel Faissol | Principal Investigator, Center for Bioengineering, Executive Director, Predictive Design of Biologics
Lawrence Livermore National Laboratory

Dr. Faissol is the Principal Investigator of the Generative Unconstrained Intelligent Drug Engineering program, which focuses on the computational design of antibodies and antigens at Lawrence Livermore National Laboratory. His primary research interest is in developing and integrating methods in machine learning, simulation, optimization and high throughput experiments to accelerate the design of biologics. Dr. Faissol joined LLNL after completing a PhD in Industrial and Systems Engineering from the Georgia Institute of Technology in 2008.

Appearances:

Pre-Congress Workshops - 21st April @ 10:00

Optimizing mAbs for Infectious Diseases

OPTIMIZING mAbs FOR INFECTIOUS DISEASES [W3] – 10am – 5pm

Room 202B

10am Workshop leader’s opening remarks: Dr Michel De Wilde, Former Senior Vice President R&D at Sanofi Pasteur & Owner, MDW Consultant LLC

Presentations: Developing improved mAbs for Infectious Diseases:

Global Health:

10.10 -10.30 Strategies to optimize mAbs for malaria

Dr Neville Kisalu, Senior Scientist, Cellular Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health

10.30 – 10.50 Development of mAbs for unmet needs in global health * Title TBC

Dr Larry Zeitlin, President, Mapp Biopharma

10.50 – 11:10 Development of mAbs to prevent vertical transmission of HIV from breastfeeding mom to infant

Marion Gruber, Vice President, Public Health and Regulatory Affairs, IAVI

Respiratory diseases:

11:10 – 11:30 Antibody engineering for ID (in vivo expression)

Antonio DiGiandomenico, Senior Director, Bacterial Antibodies, AstraZeneca

11:30 – 11:50 Developing Ab therapies that keep pace with rapidly evolving viral threats (COVID + Flu)

Dr Robert Allen, CSO, Invivyd

11:50 – 12:10 dmAb platform updates (COVID + Flu) * Title TBC

Dr Dave Liebowitz, Senior Vice President, Early-Stage Clinical Development, Inovio

12.10 – 12.30 Vaccination with Next-Generation Influenza Vaccines May Preferentially Recall Influenza Hemagglutinin-Directed Antibodies Endowed with Broadly Neutralizing Activity

Dr Giuseppe Sautto, Assistant Professor, Cleveland Clinic

12.30 – 12.50pm Computationally optimizing antibodies for infectious disease

Dr Daniel Faissol, Principal Investigator, Center for Bioengineering, Executive Director, Predictive Design of Biologics, LLNL

1pm Break

2pm Taking mAbs to the next level: Recombinant polyclonal antibody therapeutics * Title TBC

Sheila Keating, VP Immunology, Grifols

2.30pm Commercialization challenges for mAb products – understanding pathways to recommendation

Richard Hughes, Partner, Epstein Becker & Green, Professor of Law, The George Washington University Law School

3.00pm Panel: NextGen AI / computational technologies for improved vaccines and therapeutics

Introductory Presentation: Jonathan Heeney, CSO, DIOSynVax

Discussion:

Approaches to antibody-antigen interaction prediction / antigen payload synthesis

What are the challenges of computational approaches, how can we ensure more accurate/higher prediction rates

What are the implications of these new technologies for antibody and vaccine development?

What are the challenges of moving from traditional approaches to computational approaches – is it hard to keep up with technology?

Moderator: Jonathan Heeney, CSO, DIOSynVax

Dr Giuseppe Sautto, Assistant Professor, Cleveland Clinic

Dr Fadil Bidmos, UK MRC Senior (Non-Clinical) Fellow, Imperial College London

Dr Daniel Faissol, Principal Investigator, Center for Bioengineering, Executive Director, Predictive Design of Biologics, LLNL

4.15pm End of workshop